Markedly improved tumor control and survival (Fig. 1b) with increased frequency of CX3CR1+ CD8+ T cells (Fig. 1c) were observed in MC38 and CT26 tumor-bearing mice treated with ICI compared to mice receiving isotype Ab. The gene discussed is CD8A; the disease is neoplasm.